Table 2 Inhibition values of ACE2 construct against pseudotyped SARS-CoV-2 variants and SARS-CoV-1
From: Development of an ultrahigh affinity, trimeric ACE2 biologic as a universal SARS-CoV-2 antagonist
Pseudotyped SARS-CoV-2 inhibition | ||||||||
---|---|---|---|---|---|---|---|---|
Variant | IC50 (nM) | |||||||
 | ACE2 monomer | T0A | T1A | T3A | T5A | T18A | TD3ADR273Q | TD3ADH345F |
Wuhan-Hu-1 | 22 ± 5.5 | 0.6 ± 0.2 | 0.2 ± 0.1 | 0.7 ± 0.1 | 0.4 ± 0.1 | 0.1 ± 0.2 | - | - |
Delta B.1.617.2 | 24 ± 5.8 | 0.8 ± 0.4 | 0.4 ± 0.2 | 0.5 ± 0.2 | 0.2 ± 0.1 | 0.4 ± 0.1 | - | - |
Omicron BA.1 | 16 ± 4.0 | 0.2 ± 0.1 | 0.1 ± 0.02 | 0.2 ± 0.04 | 0.1 ± 0.02 | 0.03 ± 0.01 | - | - |
Arcturus XBB.1.16 | - | - | - | 0.4 ± 0.1 | - | - | 0.6 ± 0.2 | 0.4 ± 0.7 |
Pseudotyped SARS-CoV inhibition | ||||||||
 | IC50 (nM) | |||||||
 | ACE2 monomer | T0A | T1A | T3A | T5A | T18A | TD3ADR273Q | TD3ADH345F |
SARS-CoV-1 (28aa del) | 3300 ± 900 | - | - | 0.6 ± 0.2 | - | - | 1.5 ± 0.4 | 2.2 ± 0.5 |